StockData
Lakewood-Amedex Biotherapeutics Inc. logo

Lakewood-Amedex Biotherapeutics Inc. (LABT) stock

LABTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026
$0.21−0.00 (-2.23%)

Close on Nov 17, 2026Market cap $508.30KP/E –Yield –

Lakewood-Amedex Biotherapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$1.51M–
Q2 FY2026Jun 30, 2026-$3.79M–
Q1 FY2026Mar 31, 2026-$886.75K–
Q3 FY2025Sep 30, 2025-$1.88M–
Q2 FY2025Jun 30, 2025-$637.38K–
Q1 FY2025Mar 31, 2025-$542.61K–

More Lakewood-Amedex Biotherapeutics figures

See a number that looks wrong?